Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Open accessThe DOI matches its Crossref record; 121 of the 122 references it cites were found in a registry or an index.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality. It is important that all stakeholders be involved in tackling the public health threat of obesity and obesity-related diseases, including MASLD. A simple and clear assessment and referral pathway using non-invasive tests is essential to ensure that patients with severe MASLD are identified and referred to specialist care, while patients with less severe disease remain in primary care, where they are best managed. While lifestyle intervention is the cornerstone of the management of patients with MASLD, cardiovascular disease risk must be properly assessed and managed because cardiovascular disease is the leading cause of mortality. No pharmacological agent has been approved for the treatment of MASLD, but novel anti-hyperglycemic drugs appear to have benefit. Medications used for the treatment of diabetes and other metabolic conditions may need to be adjusted as liver disease progresses to cirrhosis, especially decompensated cirrhosis. Based on non-invasive tests, the concepts of compensated advanced chronic liver disease and clinically significant portal hypertension provide a practical approach to stratifying patients according to the risk of liver-related complications and can help manage such patients. Finally, prevention and management of sarcopenia should be considered in the management of patients with MASLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The growing yearly prevalence of Metabolic Dysfunction–non-alcoholic fatty liver disease (MASLD) has emerged as a worldwide public health concern, driven by improved living conditions, evolving lifestyle habits, and the widespread occurrence of obesity, diabetes, and metabolic syndrome.1”
From The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This is because the clinical definition of MASLD, as previously noted, includes not only the presence of steatosis but also a cardiometabolic context [31,32,33], which cannot be fully reproduced in a monoculture of hepatocyte-like cells.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 2×
“102 Of late, there is a growing interest in studies on the association between sarcopenia and MASLD.”
BackgroundEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Baveno VII – Renewing consensus in portal hypertension
de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., Abraldes, J. G., Albillos, A., Baiges, A., Bajaj, J., Bañares, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.022 · Cited by 2,930
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,980
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes
Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12048 · Cited by 1,155 · cited 1×
“110 Muscle strength of upper limbs and lower body strength can be assessed using the grip strength measurements and chair stand test, respectively.”
MethodDent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., Bauer, J. M., Pahor, M., Clark, B. C., Cesari, M., et al. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-018-1139-9 · Cited by 1,130 · cited 1×
“111 Increased physical activity and healthy diet have been associated with lower risk of sarcopenia and MASLD and could even reduce the risk of significant liver fibrosis.”
BackgroundA position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis
McPherson, S., Hardy, T., Dufour, J.-F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., Van Gaal, L., Schattenberg, J. M., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.453 · Cited by 945
Biggins, S. W., Angeli, P., Garcia‐Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021) · Hepatology · doi:10.1002/hep.31884 · Cited by 846
Eslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Self-citationDuell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Wong, R. J., Cheung, R., & Ahmed, A. (2014) · Hepatology · doi:10.1002/hep.26986 · Cited by 723
Villanueva, C., Albillos, A., Genescà, J., Garcia-Pagan, J. C., Calleja, J. L., Aracil, C., Bañares, R., Morillas, R. M., Poca, M., Peñas, B., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31875-0 · Cited by 711
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Franz, M. J., Boucher, J. L., Rutten-Ramos, S., & VanWormer, J. J. (2015) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2015.02.031 · Cited by 672
Farrell, G. C., Chitturi, S., Lau, G. K., Sollano, J. D., & NAFLD, F. T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05002.x · Cited by 517
Wong, V. W., Chan, W., Chitturi, S., Chawla, Y., Dan, Y. Y., Duseja, A., Fan, J., Goh, K., Hamaguchi, M., Hashimoto, E., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13857 · Cited by 506
Self-citationWong, V. W.-S., Chu, W. C.-W., Wong, G. L.-H., Chan, R. S.-M., Chim, A. M.-L., Ong, A., Yeung, D. K.-W., Yiu, K. K.-L., Chu, S. H.-T., Woo, J., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300342 · Cited by 491
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465 · cited 9×
“44 While SGLT2 inhibitors are approved for use in those without diabetes but with ischemic heart disease or heart failure, GLP1 RAs are currently only FDA approved for use in patients with diabetes or obesity.”
BackgroundInfluentialFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440 · cited 2×
“106,107 Sarcopenia is a strong predictor of mortality and morbidity for MASLD, MASH, and cirrhosis.”
BackgroundReply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature
Lazarus, J. V., Newsome, P. N., Francque, S. M., Kanwal, F., Terrault, N. A., & Rinella, M. E. (2024) · Hepatology · doi:10.1097/hep.0000000000000696 · Cited by 438
Sarcopenia and frailty in decompensated cirrhosis
Tandon, P., Montano-Loza, A. J., Lai, J. C., Dasarathy, S., & Merli, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.025 · Cited by 408
Abraldes, J. G., Bureau, C., Stefanescu, H., Augustin, S., Ney, M., Blasco, H., Procopet, B., Bosch, J., Genesca, J., Berzigotti, A., et al. (2016) · Hepatology · doi:10.1002/hep.28824 · Cited by 386
ESPEN practical guideline: clinical nutrition in liver disease
Bischoff, S. C., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Plauth, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.001 · Cited by 383
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360
Loomba, R., Lim, J. K., Patton, H., & El-Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.053 · Cited by 357
Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351
Wong, V. W.-S., Chan, R. S.-M., Wong, G. L.-H., Cheung, B. H.-K., Chu, W. C.-W., Yeung, D. K.-W., Chim, A. M.-L., Lai, J. W.-Y., Li, L. S., Sea, M. M.-M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.013 · Cited by 345
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Haam, J.-H., Kim, B. T., Kim, E. M., Kwon, H., Kang, J.-H., Park, J. H., Kim, K.-K., Rhee, S. Y., Kim, Y.-H., & Lee, K. Y. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23031 · Cited by 319
Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318
Tan, D. J. H., Ng, C. H., Lin, S. Y., Pan, X. H., Tay, P., Lim, W. H., Teng, M., Syn, N., Lim, G., Yong, J. N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00078-x · Cited by 307
Vali, Y., Lee, J., Boursier, J., Spijker, R., Löffler, J., Verheij, J., Brosnan, M. J., Böcskei, Z., Anstee, Q. M., Bossuyt, P. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.036 · Cited by 302
Latva-Rasku, A., Honka, M.-J., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., Kirjavainen, A. K., Saunavaara, V., Iozzo, P., Johansson, L., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1569 · Cited by 253
Global multi-stakeholder endorsement of the MAFLD definition
Méndez-Sánchez, N., Bugianesi, E., Gish, R. G., Lammert, F., Tilg, H., Nguyen, M. H., Sarin, S. K., Fabrellas, N., Zelber-Sagi, S., Fan, J.-G., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00062-0 · Cited by 229
Self-citation2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Review article: prescribing medications in patients with cirrhosis – a practical guide
Lewis, J. H., & Stine, J. G. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12324 · Cited by 216
Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00141-3 · Cited by 214
Self-citationAtherothrombotic risk stratification and ezetimibe for secondary prevention
Bohula, E. A., Morrow, D. A., Giugliano, R. P., Blazing, M. A., He, P., Park, J.-G., Murphy, S. A., White, J. A., Kesaniemi, Y. A., Pedersen, T. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.070 · Cited by 204
Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204
Haase, C. L., Lopes, S., Olsen, A. H., Satylganova, A., Schnecke, V., & McEwan, P. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00788-4 · Cited by 199
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Zhou, X.-D., Targher, G., Byrne, C. D., Somers, V., Kim, S. U., Chahal, C. A. A., Wong, V. W.-S., Cai, J., Shapiro, M. D., Eslam, M., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10543-8 · Cited by 194
Self-citationModelling NAFLD disease burden in four Asian regions—2019‐2030
Estes, C., Chan, H. L. Y., Chien, R. N., Chuang, W., Fung, J., Goh, G. B.-B., Hu, T. H., Huang, J., Jang, B. K., Jun, D. W., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15673 · Cited by 175
Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease
Huh, Y., Cho, Y. J., & Nam, G. E. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22021 · Cited by 173
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Targher, G., Corey, K. E., & Byrne, C. D. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101215 · Cited by 165
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Turco, L., Villanueva, C., Mura, V. L., García‐Pagán, J. C., Reiberger, T., Genescà, J., Groszmann, R. J., Sharma, B. C., Merkel, C., Bureau, C., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.050 · Cited by 132
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Chan, W., Treeprasertsuk, S., Goh, G. B., Fan, J., Song, M. J., Charatcharoenwitthaya, P., Duseja, A. K., Dan, Y.-Y., Imajo, K., Nakajima, A., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.03.006 · Cited by 114
Self-citationMertz, K. H., Reitelseder, S., Bechshoeft, R. L., Bülow, J., Højfeldt, G. W., Jensen, M., Schacht, S. R., Lind, M. V., Rasmussen, M. A., Mikkelsen, U. R., et al. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa372 · Cited by 111
Lai, L. L., Yusoff, W. N. I. W., Vethakkan, S. R., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14577 · Cited by 107
Self-citationNasimi, N., Sohrabi, Z., Nunes, E. A., Sadeghi, E., Jamshidi, S., Gholami, Z., Akbarzadeh, M., Faghih, S., Akhlaghi, M., & Phillips, S. M. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.05.011 · Cited by 93
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91 · cited 3×
“67 SGLT2 inhibitors, which have proven cardiorenal benefits, 62 can be used as adjunctive pharmacological therapy among people with T2DM and MASLD.”
BackgroundInfluentialSelf-citationGkekas, N. K., Anagnostis, P. G., Paraschou, V., Stamiris, D., Dellis, S., Kenanidis, E. I., Potoupnis, M. E., Tsiridis, E. E., & Goulis, D. G. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.01.002 · Cited by 90
Papadopoulou, S. Κ., Detopoulou, P., Voulgaridou, G., Tsoumana, D., Spanoudaki, M., Sadikou, F., Papadopoulou, V. G., Zidrou, C., Chatziprodromidou, I. P., Giaginis, C., et al. (2023) · Nutrients · doi:10.3390/nu15051104 · Cited by 90
Cho, Y., Rhee, H., Kim, Y., Lee, M., Lee, B., Kang, E. S., Soo, B., Choi, J., & Lee, Y. (2022) · BMC Medicine · doi:10.1186/s12916-022-02288-2 · Cited by 87
Nascimbeni, F., Pellegrini, E., Lugari, S., Mondelli, A., Bursi, S., Onfiani, G., Carubbi, F., & Lonardo, A. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.028 · Cited by 83
Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis
Franz, C. C., Egger, S. S., Born, C., Bravo, A. E. R., & Krähenbühl, S. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1105-5 · Cited by 79
García‐Compeán, D., Jáquez-Quintana, J. O., Lavalle-Gonzalez, F. J., Cabello, E. A. R., González, J. A., Muñoz-Espinosa, L. E., Vázquez‐Elizondo, G., Villarreal‐Pérez, J. Z., & Maldonado-Garza, H. J. (2012) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31030-0 · Cited by 74
Chan, W., Treeprasertsuk, S., Imajo, K., Nakajima, A., Seki, Y., Kasama, K., Kakizaki, S., Fan, J., Song, M. J., Yoon, S. K., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14506 · Cited by 73
Self-citationMacha, S., Rose, P. W., Mattheus, M., Cinca, R., Pinnetti, S., Broedl, U. C., & Woerle, H. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12183 · Cited by 72
Kim, D., Wijarnpreecha, K., Sandhu, K. K., Cholankeril, G. T., & Ahmed, A. (2021) · Liver International · doi:10.1111/liv.14852 · Cited by 71
Kim, H., Bae, S., Lee, M. J., Kim, E. H., Park, H., Kim, H. S., Cho, Y. K., Jung, C. H., Lee, W. J., & Choe, J. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0035 · Cited by 69
Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
Iwaki, M., Kobayashi, T., Nogami, A., Saito, S., Nakajima, A., & Yoneda, M. (2023) · Nutrients · doi:10.3390/nu15040891 · Cited by 68
Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment
Gangopadhyay, K., & Singh, P. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_512_16 · Cited by 65
Sinn, D. H., Kang, D., Kang, M., Güallar, E., Hong, Y. S., Lee, K. H., Park, J., Cho, J., & Gwak, G. (2022) · Hepatology · doi:10.1002/hep.32578 · Cited by 65
He, Y., Sabo, R., Campestrini, J., Wang, Y., Ligueros‐Saylan, M., Lasseter, K. C., Dilzer, S. C., Howard, D., & Dole, W. P. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0312-6 · Cited by 63
Treatment of Dyslipidemia in Common Liver Diseases
Speliotes, E. K., Balakrishnan, M., Friedman, L. S., & Corey, K. E. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.023 · Cited by 62
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 62
Harring, M., Golabi, P., Paik, J. M., Shah, D., Racila, A., Cable, R., Srishord, M. K., & Younossi, Z. M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.013 · Cited by 61
High prevalence of diabetes mellitus in patients with liver cirrhosis
Wlazlo, N., Beijers, H. J. B. H., Schoon, E. J., Sauerwein, H. P., Stehouwer, C. D. A., & Bravenboer, B. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03093.x · Cited by 60
Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement
Boursier, J., Anty, R., Carette, C., Cariou, B., Castéra, L., Caussy, C., Fontaine, H., Garioud, A., Gourdy, P., Guerci, B., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101272 · Cited by 55
Honda, F., Hiramatsu, A., Hyogo, H., Aikata, H., Daijo, K., Teraoka, Y., Inagaki, Y., Morio, K., Kobayashi, T., Nakahara, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195028 · Cited by 54
Costa, D., Lourenço, J., Monteiro, A. M., Castro, B., Oliveira, P., Tinoco, M. C., Fernandes, V., Marques, O., Gonçalves, R., & Rolanda, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-64141-x · Cited by 53
Chan, W., Tan, S.-S., Chan, S.-P., Lee, Y. Y., Tee, H., Mahadeva, S., Goh, K., Ramli, A. S., Mustapha, F. I., Kosai, N. R., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15787 · Cited by 53
Self-citationScheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0157-y · Cited by 48
Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study
Goh, G. B., Pan, A., Chow, W. C., Yuan, J., & Koh, W. (2016) · Liver International · doi:10.1111/liv.13241 · Cited by 45
Sindhughosa, D. A., Wibawa, I. D. N., Mariadi, I. K., & Somayana, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-11950-x · Cited by 43
Tergast, T. L., Laser, H., Gerbel, S., Manns, M. P., Cornberg, M., & Maasoumy, B. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0053-0 · Cited by 42
Drug use for non-hepatic associated conditions in patients with liver cirrhosis
the Spanish Collaborative Study Group on Therapeutic Management in Liver Diseases, Lucena, M. I., Andrade, R. J., Tognoni, G., Hidalgo, R., & de la Cuesta, F. S. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0586-2 · Cited by 37
Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease
Khoo, S., Wong, V. W., Goh, G. B., Fan, J., Chan, W., Seto, W., & Chow, W. C. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14794 · Cited by 31
Self-citationIs insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
Yen, F., Lai, J., Wei, J. C., Chiu, L., Hsu, C., Hou, M., & Hwu, C. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01773-x · Cited by 26
Chan, W. L., Chong, S.-E., Chang, F. W. S., Lai, L. L., Chuah, K. H., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2023) · Hepatology International · doi:10.1007/s12072-023-10550-9 · Cited by 25
Self-citationZhao, X., Shi, X., Gu, H., Zhou, W., & Zhang, Q. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16150 · Cited by 22
Addepally, N. S., George, N. E., Martínez-Macías, R. F., García-Saenz-de-Sicilia, M., Kim, W. R., & Duarte‐Rojo, A. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5265-3 · Cited by 21
Ng, C. H., Teng, M. L. P., Chew, N., Chan, K. E., Yong, J. N., Quek, J., Tan, D. J. H., Lim, W. H., Lee, G. S. J., Wong, J., et al. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2119128 · Cited by 21
Dwinata, M., Putera, D. D., Adda’i, M. F., Hidayat, P. N., & Hasan, I. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i5.464 · Cited by 16
Endorsing the redefinition of fatty liver disease
Tan, S. S., Lee, Y. Y., Ali, R. A. R., Mustapha, F. I., & Chan, W. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00002-9 · Cited by 16
Self-citationMohammed, O. K., & Mahadeva, S. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12978 · Cited by 9
Kannampilly, J. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0166 · Cited by 9
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus
Gentile, S., Guarino, G., Strollo, F., Romano, M., Genovese, S., Masarone, M., & Ceriello, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.006 · Cited by 9
Shahrani, S., Gill, S., Sooi, C., Skantha, R., Kumar, C., Limun, M. F., Affendi, N. A. N. M., Chuah, K.-H., Khoo, S., Rajaram, R., et al. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16313 · Cited by 5
Self-citationKaruthan, S. R., Koh, P. S., Chinna, K., & Chan, W. K. (2021) · PubMed · Cited by 4
Self-citationHepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Teng, M. L. P., Tan, D. J. H., Ng, C. H., & Huang, D. Q. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0069 · Cited by 4
Cited by
Bays, H. E., Kirkpatrick, C. F., Maki, K. C., Toth, P. P., Morgan, R. T., Tondt, J., Christensen, S. M., Dixon, D. L., & Jacobson, T. A. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.04.001 · Cited by 166
Wang, L., Berger, N. A., Kaelber, D. C., & Xu, R. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.04.029 · Cited by 147
Miller, D. M., McCauley, K. F., & Dunham‐Snary, K. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70132 · Cited by 152
Current and emerging strategies for the prevention of hepatocellular carcinoma
Yeo, Y. H., Abdelmalek, M. F., Khan, S. A., Moylan, C. A., Rodriquez, L. M., Villanueva, A., & Yang, J. D. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01021-z · Cited by 110
Vesković, M. N., Šutulović, N., Hrnčić, D., Stanojlović, O. P., Μacut, D., & Mladenović, D. R. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110570 · Cited by 115
Metadata
- Authors
- Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R.
- Affiliations
- University of Malaya (MY)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Chan, Wah-Kheong
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2023-09-13
- Volume
- 32
- Issue
- 3
- Pages
- 197-213
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC10583766
- OpenAlex
- W4386704735
- Cited by
- 776
- References
- 122
- Citations by year
- 2026: 245 · 2025: 342 · 2024: 183 · 2023: 5
- FWCI
- 30.29
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, metabolic syndrome, obesity, chronic liver disease, non-invasive liver assessment, referral pathways, lifestyle intervention, cardiovascular risk, anti-hyperglycemic drugs, liver cirrhosis, decompensated cirrhosis, compensated advanced chronic liver disease, clinically significant portal hypertension, sarcopenia, liver complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.